BOCA RATON, Florida, February 16, 2022 / PRNewswire / – Hip Innovation Technology, LLC (HIT), a medical device manufacturing company that develops innovative orthopedic solutions to improve the quality of life and patient care, is pleased to announce the addition of key senior executives to the company’s executive team. Stephen MacDonald, MD, has joined HIT as Chief Research Officer (CSO), and Frank Maas will serve as Chief Operating Officer (COO).
“Steve and Frank have decades of professional success in developing medical devices, managing regulations and commercializing the market,” he said. George Diamantoni, co-founder and CEO of HIT. “Their respective contributions to our core research design and the planned 2022 launch of our Hip Replacement System (Reverse HRS) have been significant, and their industry-leading expertise will play a crucial role in the company’s continued growth.”
Doctor Stephen J. McDonald is a professor and chairman of orthopedic surgery J. K. Kennedy University of Western Ontario y London, Ontario, Canada. He is a member and leader of many orthopedic organizations, including the North American Hip Society, the International Hip Society, and the North American Knee Society. Dr. MacDonald has served as president of the North American Knee Society and the Canadian Society of Arthroplasty, and has received numerous awards for his orthopedic experience and contributions to the profession, including Frank Stinchfield Award from the Hip Society and John Insal Knee Society Award.
Dr. MacDonald is an internationally recognized leader in hip and knee replacement. He has received more than 25 research grants for hip and knee replacement projects $ 5 million. He has published more than 200 scientific papers and book chapters and lectured at more than 250 national and international meetings.
“I am pleased to officially join the HIT team. I have watched the development of this new technology from concept to strong bench trials and its ongoing international clinical trials, ”said Dr. MacDonald. “Each step builds on previous successes, culminating in a major FDA IDE clinical trial scheduled to begin in 2022. HIT will continue to build a proven platform for Reverse HRS. ”
A veteran of the industry Frank Maas is the head of medical devices with more than 30 years of experience in orthopedics, spine and arthroscopy. Most recently, Frank was a senior vice president at Arthrex, Inc., a private multibillion-dollar arthroscopic and orthopedic company. During his 16-year career at Arthrex, he was responsible for the engineering, research and development departments, regulatory work, quality assurance and clinical affairs, where he helped drive Arthrex’s unprecedented growth through new product development and FDA / CE regulatory approval. Mark on hundreds of new arthroscopic items. and orthopedic systems. Prior to Arthrex, Frank spent five years as Director of Regulatory and Clinical Affairs at DePuy Spine, Johnson and Johnson, where he was responsible for FDA approval of the first artificial vertebral disc in the United States. Prior to DePuy Frank worked at Howmedica. / Stryker Orthopedics for 10 years in quality assurance and regulatory positions.
“I am excited to be part of HIT’s senior management team and look forward to working with my colleagues, surgeons and regulators to ensure that this exciting new technology becomes available to many patients who can benefit from its new design,” he said. Frank Maas“With so little innovation in orthopedic reconstruction, providing an FDA-approved US clinical trial IDE further confirms the potential benefits of this important device.”
About the Reverse HRS System
Reverse HRS is a prosthesis of the hip joint with the opposite geometry of metal on polyethylene, designed to improve stability over extended ranges and reduce the risk of dislocation. Like most conventional systems, the Reverse HRS consists of a femoral leg, an acetabulum and a cobalt-chrome ball that is hinged in a plastic backing. Unlike existing full hip arthroplasty systems, the ball is placed on a shoe in the acetabulum instead of the femur, and a plastic liner is attached to the femur, which is then attached to the femur as opposed to a polyethylene liner. attached to the acetabulum. This technological difference does not alter the center of rotation of the reverse HRS and remains similar to normal physiological hip arthroplasty or a well-placed traditional full hip arthroplasty. The advanced Reverse HRS implant is designed to provide greater range of motion in all planes, increase hip stability and reduce the risk of dislocation. Importantly, Reverse HRS also provides variability in component placement, including higher lead angles and anteversion of the acetabulum. The femoral bowl is assembled around the acetabulum and overlaps with the acetabulum when the femur is subjected to flexion-extension, abduction-reduction, and internal-external rotation. Such a forgivable design can compensate for suboptimal component placement, which can provide benefits such as extended range of motion, hip stability, and reduced impact probability. Reverse HRS is designed to untie the relationship between component placement, wear and stability. This unique Reverse HRS implant design provides optimal surface area contact between the acetabulum and the femoral cup, which can eliminate the load on the edge. Elimination of the edge load can provide benefits that include reduction of high contact stresses, reduction of implant wear and uniform wear, which minimizes the formation of wear residues and related problems associated with osteolysis.
About Hip Innovation Technology, LLC
Headquarters in the village Boca Raton, Florida, Hip Innovation Technology was established in 2011 to provide market-leading solutions for orthopedic devices that improve the quality of life and care of patients. In partnership with healthcare professionals around the world, our goal is to identify unmet clinical needs, then develop, manufacture and ultimately bring to market innovative orthopedic reconstructive and related surgical solutions.
For more information, visit www.hipinnovationtechnology.com.
Caution against statements about the future
This news release may contain forward-looking statements in terms of the safe harbor provisions of the Private Securities Judicial Reform Act of 1995. Statements that look to the future include, but are not limited to, statements regarding the expectations, plans, prospects of Hip Innovation Technology, and product and service offerings, including new product launches and potential clinical successes. Such statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties that could lead to significant differences in actual results and outcomes. Hip Innovation Technology disclaims any intent or obligation to update or revise any forward-looking statements, as a result of receiving new information, future events or otherwise. Accordingly, such forward-looking statements speak only of the date made. Readers of this news release are warned not to rely too heavily on these forward-looking statements because, although management believes that the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will be accurate. This warning statement applies to all forward-looking statements contained in this news release.
Hip Innovation Technology
John F. Kuten
JFK Communications, Inc.
SOURCE Hip Innovation Technology